Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Self-Amplifying RNA vaccines show promise in early COVID-19 trial

NCT ID NCT05037097

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 41 times

Summary

This study tested three new self-amplifying RNA vaccines against COVID-19 in 72 healthy adults, some already vaccinated and some not. The goal was to check safety and how well the vaccines boost the immune system. Results help decide which vaccine candidates to study further.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Arcturus Investigational Site 101

    Singapore, 169608, Singapore

  • Arcturus Investigational Site 201

    Kansas City, Missouri, 64114, United States

  • Arcturus Investigational Site 202

    Wichita, Kansas, 67207, United States

  • Arcturus Investigational Site 301

    Diepkloof, Soweto, 1862, South Africa

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease Orthocoronavirinae infectious disease COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.